Advanced search×
×

Vascular Pharmacology

Print ISSN
1537-1891
Electronic ISSN
1879-3649
Impact factor
2.174
Publisher
Sciencedirect
URL
http://www.sciencedirect.com/science/journal/15371891
Usage rank
4675
Article count
4354
Free count
8
Free percentage
0.00183739
PDFs via platforms
Rcgp, Gale, Sciencedirect, and Ingenta

  1. Biomarkers of inflammation and endothelial function: the holy grail of experimental and clinical medicine?

    Vascular Pharmacology 56(1-2):26 (2012) PMID 22198643

    Drug induced vasculitides in humans are relatively rare diseases, resembling drug-induced vasculitis in rodents and primary idiopathic vasculitis. Because of their exquisite inflammatory nature, vascular lesions in these conditions release a large amount of bioactive molecules and ac...
  2. The effect on ephedrine prodrugs on locomotor activity in rats.

    Vascular Pharmacology 27(1):109 (1996) PMID 8742505

    1. Five oxazolidines were synthesized by reaction of (-) ephedrine with formaldehyde, propionaldehyde, butyraldehyde, isobutyraldehyde, and acetone, respectively. 2. Half-lives of hydrolysis were measured in pH 7.4 aqueous buffer. Half-lives varied from 12 seconds to 11 minutes. 3. The compounds wer...
  3. "Your Paper, Your Way" - A new initiative by Vascular Pharmacology.

    Vascular Pharmacology 59(5-6):119 (2013) PMID 24300412

  4. Clopidogrel "resistance": pre- vs post-receptor determinants.

    Vascular Pharmacology 59(5-6):152 (2013) PMID 24140755

    We therefore postulate that "resistance" to clopidogrel arises via a combination of pharmacogenetic, pharmacokinetic and intracellular biochemical mechanisms. Considerable attention has been so far directed to the finding that stent thrombosis occurs more frequently in patients with loss-of-function...
  5. Is type 2 diabetes really a coronary heart disease risk equivalent?

    Vascular Pharmacology 59(1-2):11 (2013) PMID 23702159

    The concept of diabetes as a coronary heart risk (CHD) equivalent postulates that patients with diabetes who do not yet have CHD are at an equally high cardiovascular risk as non-diabetic patients with CHD. This implies important therapeutic, psychological, and economical consequences. However, wher...
  6. Angiostatin inhibits endothelial MMP-2 and MMP-14 expression: a hypoxia specific mechanism of action.

    Vascular Pharmacology 58(4):280 (2013) PMID 23220260

    We investigated the effects of angiostatin on endothelial cell migration and apoptosis during hypoxia. Human microvascular endothelial cells (HMVEC-L) were exposed to angiostatin under normoxic or hypoxic conditions. Apoptosis was measured by flow-cytometry. HMVEC-L migration was studied using a mod...
  7. Insights into gene therapy for critical limb ischemia: The devil is in the details

    Vascular Pharmacology 57(1):10 (2012) PMID 22580542

    Patients with critical limb ischemia (CLI) without potential for revascularization are currently without alternate therapies. Several gene therapy trials have tested angiogenesis factors, hepatic growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, in resc...
  8. Arachidonic acid inhibits Na⁺-K⁺-ATPase via cytochrome P-450, lipoxygenase and protein kinase C-dependent pathways in sheep pulmonary artery...

    Vascular Pharmacology 56(1-2):84 (2012) PMID 22155164

    The purpose of the study was to examine whether arachidonic acid inhibits vascular Na(+)-K(+)-ATPase in pulmonary vasculature and if so, what are the mechanisms involved. Functional Na(+)-K(+)-ATPase activity was studied in terms of K(+)-induced relaxation in sheep pulmonary arterial...
  9. Taxol alleviates 2-methoxyestradiol-induced endothelial permeability.

    Vascular Pharmacology 56(1-2):56 (2012) PMID 22074808 PMCID PMC3268947

    We have previously shown that the anti-cancer agent 2-methoxyestradiol (2ME) induces hyperpermeability across endothelial monolayers. Here, we show that both microtubule disruptor, 2ME, and microtubule stabilizer, paclitaxel (taxol), increase vascular lung permeability in vitro and in vivo. Simultan...
  10. Cellular and molecular mechanisms of vascular injury in diabetes — Part II: Cellular mechanisms and therapeutic targets

    Vascular Pharmacology 54(3):75 (2011) PMID 21453785

    We summarize the evidence for such an occurrence. We also here highlight how new insights into pathways of vascular damage in diabetes may indicate new targets for preventive and treatment strategies....